TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05215067
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion,Specified dose on specified days
Study: NCT05215067
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion,Specified dose on specified days
Study: NCT05090124
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.
Study: NCT05902169
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula:~Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\].
Study: NCT05902169
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed and administered per labelling.
Study: NCT05902169
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosed and administered per labelling.
Study: NCT06459310
Drug: Metformin Hydrochloride tablet
Normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Extended release oral tablets, 1000 mg/day, single dose
Study: NCT04982224
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by IV infusion
Study: NCT04923542
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
Study: NCT06793748
Drug: TISSEEL Fibrin Sealant KIT
Normalized name: TISSEEL Fibrin Sealant KIT
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin Sealant (TISSEEL® VH SD Kit)
Study: NCT05386043
Drug: FET F-18
Normalized name: FET F-18
DrugBank: FET F-18 (DB15405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET scan with FET prior to biopsy
Study: NCT05386043
Drug: O-15 Radioisotope
Normalized name: water, O-15
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET scan with O-15 Water prior to biopsy
Study: NCT06206408
Drug: Fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04774237
Drug: Carbachol
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single drop in each eye at a visit.
Study: NCT06484985
Drug: AXT-1003
Normalized name: Axtle
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Study: NCT04514497
Drug: Elimusertib
Normalized name: Elimusertib
DrugBank: Elimusertib (DB19041)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04514497
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04514497
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05327686
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05327686
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05327686
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06315010
Drug: Repotrectinib
Normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid.
Study: NCT05579327
Drug: Tiratricol
Normalized name: tiratricol
DrugBank: Tiratricol (DB03604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiratricol tablets are flat tablets that contain 350 µg tiratricol. Treatment will be administered orally or via percutaneous endoscopic gastrostomy (PEG) tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable.
Study: NCT06250205
Drug: Obicetrapib
Normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05086744
Drug: Iptacopan
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan 200 mg BID given orally (capsule)
Study: NCT05133297
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets administered at 5 mg BID daily for 24 weeks.
Study: NCT04756427
Drug: Sodium Citrate 4% Inj Syringe 3Ml
Normalized name: SODIUM CITRATE 4% INJ SYRINGE 3ML
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
Study: NCT04836429
Drug: Porfimer Sodium
Normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05214482
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion,Specified dose on specified days
Study: NCT05214482
Drug: AK117
Normalized name: Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer
DrugBank: Ligufalimab (DB17542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion,Specified dose on specified days
Study: NCT05227144
Drug: ORIC-533
Normalized name: Oriconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ORIC-533 once daily in consecutive 28-day cycles
Study: NCT04684108
Drug: SG301
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
Study: NCT05892432
Drug: Semaglutide 3 MG [Rybelsus]
Normalized name: semaglutide 3 MG [Rybelsus]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
Study: NCT05892432
Drug: Semaglutide 7 MG [Rybelsus]
Normalized name: semaglutide 7 MG [Rybelsus]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
Study: NCT05743621
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg daily PO
Study: NCT04889430
Drug: Iptacopan
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan 200mg twice daily oral
Study: NCT06792344
Drug: anti-CD19 CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-targeting CAR-T cells
Study: NCT05554939
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
Study: NCT06087614
Drug: Cisplatin injection
Normalized name: cisplatin Injection
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent chemotherapy, weekly Inj Cisplatin 40mg/m2. This will be given if clinically indicated
Study: NCT06799845
Drug: bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration
Study: NCT05809908
Drug: Tricaprilin
Normalized name: TRICAPRILIN
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of IMP will be administered orally 30 minutes after completing a meal.~There is 1 g of tricaprilin per 2 ml of AC-OLE-01-VA.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of tricaprilin; 80 ml total daily dose of AC-OLE-01-VA, over the course of 3 weeks.
Study: NCT04760613
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg oral daily use (each capsule of active drug contains 50 mg of CBD)
Study: NCT06407973
Drug: Latanoprost plus adjunctive glaucoma medication
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* Adjunctive topical glaucoma medication(s) as selected by the Investigator
Study: NCT05560529
Drug: TAU
Normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving TAU (usual pharmacotherapy in BED) over 20 weeks
Study: NCT06170489
Drug: Bendamustine or gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Investigator-Selected chemotherapy of EITHER bendamustine by IV infusion at a dose of 90 or 120 mg/m\^2 on Day 1 and Day 2 of either a 3- or 4-week cycle for up to 6 cycles OR gemcitabine by IV infusion at a dose of 1000 mg/m\^2 on Day 1 and Day 8 of a 3-week cycle for up to 6 cycles.
Study: NCT04953104
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04962126
Drug: Obinutuzumab 25 MG/1 ML Intravenous Solution
Normalized name: Obinutuzumab 25 MG/1 ML Intravenous Solution
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles.
Study: NCT06161532
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan is administered IV at 10 mg/kg on days 1 and 8 of each 21-day cycle.
Study: NCT06161532
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is administered IV at 1200 mg on day 1 each 21-day cycle.
Study: NCT05103904
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05012631
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan dosing for participants \<16 years will be 0.7 mg/kg (maximum of 50 mg) once daily. The dose can be increased to 1.4 mg/kg (maximum of 100 mg once daily) after 2 weeks if the dose was tolerated (no hypotension or hyperkalemia). For patients ≥16 years, the starting dose will be 50 mg once daily which can be increased to 100 mg daily if tolerated after 2 weeks.
Study: NCT06784843
Drug: Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block
Normalized name: Aldex AN
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
Study: NCT06784843
Drug: Midazolam as an adjuvant to local anesthesia for peribulbar block
Normalized name: Aldex AN
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
Study: NCT06783140
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel Powder For Injectable Suspension Nanoparticle, Albumin-bound Paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity.
Study: NCT06783140
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is a hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity.
Study: NCT06783140
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin is an alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.
Study: NCT06790420
Drug: Rituximab Pfizer
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
Study: NCT06790420
Drug: Rituxan
Normalized name: Rituxan
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For the acute therapy, Rituximab is administrated once a week up to 8 times and for maintenance therapy, it is administrated every 8 weeks up to 12 times
Study: NCT06206564
Drug: Artesunate ointment
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
Study: NCT06143670
Drug: Stannous fluoride toothpaste
Normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.454% w/w SnF2
Study: NCT06143670
Drug: Sodium fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.243% w/w Sodium fluoride
Study: NCT06785974
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily 20mg atorvastatin.
Study: NCT04699188
Drug: TNO155
Normalized name: SHP2 inhibitor TNO155
DrugBank: Batoprotafib (DB19137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP2 inhibitor
Study: NCT06790966
Drug: Pembrolizumab Monotherapy
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (IV) every 3 weeks for up to 35 cycles.
Study: NCT05922878
Drug: ALTO-300
Normalized name: Altoprev
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALTO-300 capsule QD
Study: NCT06783686
Drug: NV701
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: eye drop
Study: NCT06783686
Drug: Pilocarpine 1.25% Eye drop
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eye drop
Study: NCT06784024
Drug: Lidocaine topical
Normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical lidocaine (SPRAY SOLUTION 10 g) 10% will be applied to the cervix and cervical canal prior to the MVA procedure in a number of 20 sprays separated by 3 seconds between each spray (0.06 ml/spray).
Study: NCT06783816
Drug: chimeric antigen receptor gene modified T cells
Normalized name: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.
Study: NCT00189722
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05863273
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.
Study: NCT06789848
Drug: Ligufalimab
Normalized name: Ligufalimab
DrugBank: Ligufalimab (DB17542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligufalimab (AK117) 45 mg/kg IV over 120 minutes on Day 1 every 3 weeks
Study: NCT06789848
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab (AK104) 10 mg/kg IV over 60 minuets at least 30 minutes after Ligufalimab on Day 1 every 3 weeks
Study: NCT05150795
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
Study: NCT06087835
Drug: Zibotentan/Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
Study: NCT06087835
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive dapagliflozin as per the arms they are randomized to
Study: NCT06566833
Drug: Casein phosphopeptide amorphous calcium phosphate
Normalized name: caseins
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: remineralizing agents that acts as a fluoride booster
Study: NCT06566833
Drug: 5% sodium fluoride varnish
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remineralizing agent that is used as a gold standard for remineralization
Study: NCT06592547
Drug: Intravenous metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous beta-blockers, recieved FDA approval
Study: NCT05099172
Drug: BAY2927088_formulation A
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06376162
Drug: Ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06376162
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT06376162
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05776979
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by vein over about 75 minutes
Study: NCT05776979
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT05241275
Drug: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
Study: NCT05446298
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
Study: NCT06582524
Drug: Pegzilarginase
Normalized name: Pegzilarginase
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are \< 24 months of age
Study: NCT05428033
Drug: centanafadine capsule
Normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT06799884
Drug: Aprocitentan
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet of aprocitentan 25 mg
Study: NCT04995484
Drug: Belzutifan
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 40 mg tablets given as a single oral 80 mg dose.
Study: NCT05815173
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.